FDA Approves GSK's Hibsago For Chronic Hepatitis B In Adults Without Cirrhosis

LONDON (dpa-AFX) - GSK plc (GSK) announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) to treat chronic hepatitis B (CHB) virus infection in combination with...
This is a short summary. The full story is published by Finanznachrichten.de.
Read full story at Finanznachrichten.de

